Caidreamh a thuiscint idir MRD agus teiripe CAR T-Cell
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Teiripe gascheall mesenchymal i neamhoird néareolaíocha
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
Tugann FDA ainmniúchán druga dílleachta do CART T-Cell Therapy A2B530 le haghaidh cóireáil ailse cholaireicteach
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Tá Amtagvi Iovance ceadaithe ag USFDA mar an chéad theiripe T-chealla le haghaidh meall soladach
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Tá Amivantamab-vmjw ceadaithe ag an USFDA le haghaidh tásca ailse scamhóg neamh-bheag cille EGFR exon 20 a cuireadh isteach
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Tá Osimertinib le ceimiteiripe ceadaithe ag an USFDA le haghaidh ailse scamhóg neamh-bheag cille EGFR-mutated
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Tá Lifileucel faofa ag an USFDA le haghaidh meileanóma neamh-dhírithe nó meiteastatach
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Tá Tepotinib ceadaithe ag an USFDA le haghaidh ailse scamhóg meiteastatach neamh-bheag cille
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Tá liposome Irinotecan ceadaithe ag an USFDA le haghaidh cóireáil chéad líne ar adenocarcinoma pancreatach meiteastach
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Tá Erdafitinib ceadaithe ag USFDA le haghaidh carcinoma urothelial chun cinn go háitiúil nó metastatach
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..